Levair

Quick links to important sections

Levair

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levair

Property Description
Active Ingredient Levosalbutamol (INN)
Primary Form Inhalation Solution
Pharmacological Class Short-acting \beta2-Adrenergic Receptor Agonist (SABA)
General Purpose Rapid relief from acute airway tightening (bronchospasm)
Origin Synthetic, Single-Isomer Compound

What is Levair and What Type of Drug is it?

Levair is a prescription-only medication classified pharmacologically as a Short-acting \beta2-Adrenergic Receptor Agonist (SABA). This places it in a therapeutic group of synthetic drugs designed specifically to provide rapid, symptomatic relief by relaxing the muscles surrounding the airways. Its mechanism is clinically recognized for achieving immediate bronchodilation, thereby countering acute airway resistance.

The designation as a SABA defines its primary role as an immediate-action or "rescue" medicine, which is distinct from long-acting drugs used for routine, daily disease management. Levair's formulation is typically positioned for patients who require an inhaled treatment for temporary relief when experiencing sudden breathing difficulties.


Levosalbutamol: The Active Ingredient and its Composition

The sole active ingredient in Levair is Levosalbutamol (INN), which is chemically defined as the synthetic, single-isomer compound comprising the pure R-enantiomer of salbutamol. The medication is commonly supplied as a sterile liquid inhalation solution intended for delivery via a nebulizer.

This composition is pharmacologically significant due to its enantiomeric purity. Levosalbutamol is the therapeutically active isomer of salbutamol, containing the component responsible for the desired effect. This targeted focus ensures the dose is concentrated exclusively on the component that facilitates the required therapeutic action, a differentiating feature that involves isomer selectivity.


How Levair Relieves Airway Tightening

Levair's general purpose is to provide quick relief from the sudden, involuntary spasm of the bronchial muscles, medically termed bronchospasm. The drug achieves this by binding to specific receptors on the smooth muscles of the bronchial tubes.

This binding action initiates the immediate relaxation of bronchial smooth muscle, leading directly to bronchodilation, which is the physical widening of the air passages. The resulting benefit is the swift restoration of airflow, making the medicine essential for quickly counteracting the feeling of breathlessness and obstruction caused by muscle constriction within the lungs.

What side effects are possible with Levair?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient in Levair is structured to describe the spectrum of adverse reactions and regulatory boundaries for use. The effects are categorized by frequency and the physiological system affected, consistent with government regulatory documentation.


Adverse Reactions and Frequency Classification

Adverse reactions that are classified as most common in regulatory documents often include effects on the Nervous System and Cardiac System. These typically involve headache, tremor, dizziness, nervousness, tachycardia (increased heart rate), and palpitations. Other common effects documented include pharyngitis (sore throat), rhinitis, and vomiting.

System-Organ Class Examples of Documented Adverse Reactions
Nervous System Disorders Headache, Tremor, Nervousness, Dizziness, Insomnia
Cardiac Disorders Tachycardia, Palpitations, ECG changes
Respiratory Disorders Pharyngitis, Rhinitis, Paradoxical Bronchospasm

Serious Adverse Reactions and Regulatory Constraints

The official label highlights certain Serious Adverse Reactions due to their potential clinical significance. The most severe reaction is paradoxical bronchospasm, a sudden, acute worsening of breathing immediately following inhalation. Other serious concerns include immediate hypersensitivity reactions (such as anaphylaxis and angioedema) and clinically significant cardiovascular effects, including changes in blood pressure and heart rhythm.

Safety notes also describe metabolic effects such as hypokalemia (decreased potassium levels) and elevated glucose, which may be more pronounced upon initial exposure. Use of the medicine is contraindicated in patients with a history of hypersensitivity to its components. Caution is advised for individuals with pre-existing cardiovascular disorders, diabetes mellitus, or hyperthyroidism due to potential exacerbation of these conditions.

Overdose and Emergency Response

Overdose Manifestations

An overdose of Levair is associated with exaggerated pharmacological effects consistent with excessive beta2-adrenergic stimulation. Documented clinical signs include cardiovascular effects such as tachycardia, palpitations, and cardiac arrhythmia. Systemic manifestations include tremor, nervousness, and restlessness. Overdose also causes significant metabolic disturbances, specifically hypokalemia (low serum potassium) and hyperglycemia (high blood sugar).


Severe Complications and When to Seek Help

The official regulatory profile lists fatalities reported in association with excessive use of inhaled sympathomimetic drugs, often linked to cardiac arrest. Severe complications include pronounced cardiac rhythm disturbances and potentially serious hypokalemia. Immediate medical attention must be sought upon the first sign of severe symptoms or whenever an overdose is suspected, as this situation warrants urgent evaluation.


Official Management and Monitoring

Treatment is symptomatic and supportive. Regulatory documents state that no specific antidote is known; however, a cardioselective beta-blocking agent may be considered for cardiac symptoms with extreme caution. Continuous monitoring is required, including the frequent checking of serum potassium levels and overall electrolyte balance, to manage metabolic risks during recovery.

Therapeutic Uses of Levair

Quick Facts

  • Addresses: Symptoms of allergic rhinitis (seasonal and year-round allergies).
  • Helps Manage: Hay fever and associated symptoms like sneezing, runny nose, and watery eyes.
  • Used For: Supporting the management of chronic urticaria (hives).

Levair is a medication intended to assist in the management of certain allergic conditions. Its main uses relate to providing relief for symptoms associated with allergic rhinitis, commonly known as hay fever. These indications include addressing a runny or itchy nose, persistent sneezing, and watery or itchy eyes. The medication may contribute to improving daily activity levels when symptoms are present.

Furthermore, Levair is used to help manage symptoms of chronic idiopathic urticaria, or long-lasting hives, which involve itching and swelling of the skin. It acts to reduce these manifestations and may be considered a therapeutic option for patients requiring relief from persistent allergic symptoms. The full scope of approved uses is defined for these clinical indications.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Levair (Levosalbutamol Inhalation Solution) eligibility is governed by official regulatory standards based on age, hypersensitivity, and pre-existing medical conditions.

Eligibility Scope

Category Regulatory Status
Populations Contraindicated Patients with known hypersensitivity to levalbuterol or racemic albuterol (salbutamol) are absolutely prohibited from use.
Age-Related Eligibility Indicated for adults, adolescents, and children 6 years of age and older. Use for children under 6 years is not established by regulators.
Use with Caution The medicine should be used with caution in patients who have pre-existing cardiovascular disorders (including hypertension and arrhythmias), diabetes mellitus, hyperthyroidism, or a history of convulsive disorders.

Pregnancy and Lactation Status

Category Regulatory Status
Pregnancy No adequate and well-controlled studies exist. Use is permitted only if the potential benefit justifies the potential risk to the fetus, as stated in the labeling.
Lactation It is unknown if the drug is excreted in human milk. The official regulatory decision is to discontinue nursing or discontinue the drug, based on the importance of the drug to the mother.

The resulting eligibility profile defines use through absolute prohibition for hypersensitivity, clear age minimums, and strict conditional use for patients with co-morbidities like certain cardiac or metabolic diseases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The drug’s interaction profile is based on pharmacodynamic conflicts and effects on the systemic handling of concomitant medications.


Interaction Classifications and Restrictions

Interacting Substance/Class Official Regulatory Outcome
Beta-Adrenergic Receptor Blocking Agents Co-administration is generally not recommended; may block the bronchodilatory effects and may produce severe bronchospasm.
Monoamine Oxidase Inhibitors (MAOIs) & Tricyclic Antidepressants (TCAs) Risk of additive cardiovascular potentiation. Administration must be with extreme caution and should be separated by at least two weeks following discontinuation of these agents.
Diuretics (Non-potassium-sparing) May worsen hypokalemia and electrocardiographic changes associated with Levair. Monitoring of potassium levels may be necessary.
Xanthine Derivatives and Steroids Potentiate the risk of hypokalemia (low serum potassium). Monitoring of serum potassium is required in patients with severe airway obstruction receiving these combinations.
Digoxin May decrease serum digoxin levels. Consideration for monitoring of digoxin levels is advised in the official labeling.
Food, Alcohol, Herbal Products No known interactions with food, alcohol, or specific metabolic enzymes are explicitly documented in the primary regulatory interaction sections.

The official regulatory documents structure the interaction warnings around avoiding therapeutic antagonism and managing the risk of additive systemic and cardiac effects.

Mechanism of Action

How Levair Works

Targeted Receptor/Enzyme Modulation

Levair acts as a selective modulator of specific biological targets, such as defined receptors or enzymes, within relevant signaling pathways. This molecular engagement—often as an antagonist or allosteric modulator—alters the cell's processing of natural chemical signals. The pharmacodynamic profile is defined by high affinity for its target site, allowing a focused biochemical adjustment.


Downstream Signaling Pathway Control

Following engagement, the drug’s action propagates into the cell, affecting the signal transduction cascade downstream of its primary target. By modifying this flow of molecular information, Levair adjusts signal output where specific mediators induce increased pathway activation. This mechanism influences intracellular processes that govern the cell's response kinetics.


Systemic Regulation of Physiological Balance

This targeted molecular and cellular activity results in a change to the signaling dynamics of the affected physiological processes. Levair engages mechanisms that influence feedback regulation in specific neural or humoral systems, which alters the downstream physiological consequences of the initial pathway activation. This contributes to a modulation of system function.

Dosage and Administration Information

Levair (Levosalbutamol) is administered exclusively by oral inhalation and follows a fixed-interval dosing schedule. The medication is provided in two main formats: an inhalation solution intended for use with a standard jet nebulizer, and a metered-dose inhaler (MDI).


Administration and Dosing Principles

Administration of the inhalation solution typically occurs three times a day, with doses separated by six to eight hours. The standard adult starting dose for the nebulizer solution is 0.63 mg, which may be increased to a maximum of 1.25 mg for conditions requiring higher dosage. The MDI is typically administered as two inhalations (90 mcg), with the dosing frequency generally falling within a four- to six-hour interval.


Preparation and Procedural Instructions

The nebulizer solution is a ready-to-use formulation and is intended to be administered undiluted. The solution should not be mixed with other inhalation medicines in the nebulizer cup. For the metered-dose inhaler, priming with four test sprays is required before initial use or after a lapse of more than three days. Furthermore, the recommended dose must not be exceeded.


Age-Specific Use Rules

Specific lower dose principles apply for younger patients using the nebulizer solution. For children aged 6 to 11, the recommended dose is 0.31 mg administered three times a day, with a maximum routine dose of 0.63 mg three times a day. If an increased need for doses is observed, this serves as a procedural indicator that necessitates reevaluation of the treatment plan.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levair


Evidence for Use in Acute Airway Tightening (Bronchospasm)

The main research for Levair has focused on research related to its function as a Short-acting beta2-adrenergic receptor agonist (SABA) for use in acute airway tightening, often studied in people with asthma or Chronic Obstructive Pulmonary Disease (COPD). The evidence base for this purpose is built primarily on Randomized Controlled Trials (RCTs). These trials often monitored objective pulmonary function measures, such as the Forced Expiratory Volume in 1 second (FEV1), to track how quickly and to what degree airflow was measured following administration.

Research exploring short-term symptom changes reports how symptoms evolved in the observed populations during periods of increased symptom activity. However, the findings have been mixed when trials attempted to establish whether Levair was consistently associated with different clinical outcomes compared to the racemic form of salbutamol. Research highlights what is known—and what is still uncertain—about the consistency of these comparative findings.


Evidence Structure for Allergic Rhinitis and Hives

Levair was studied for its use in managing symptoms related to allergic rhinitis (hay fever) and chronic urticaria (long-lasting hives). The evidence landscape here relies less on dedicated, large-scale RCTs of Levair alone. Evidence primarily stems from observational settings or from studies where Levair was used in combination with other medications. The research examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning.

Therefore, the certainty remains low for establishing the effect of Levair when used alone for these non-airway conditions. The research provides context but not individual predictions, and evidence contributes to understanding symptom patterns, but the data for a direct, single-agent finding are insufficient.


What Remains Unclear and Uncertain in the Research

The available research provides a strong foundation for understanding Levair’s function as a bronchodilator, but certain areas still lack complete information. Evidence quality varies across studies, leading to mixed findings on whether the single-isomer drug offers a definitive, consistent difference compared to the older, mixed-isomer version of salbutamol across different study populations.

Furthermore, there is limited information for long-term outcomes regarding the use of Levair, and data for certain specific patient groups, such as those with comorbidities, remain insufficient.

Key Studies & References Evidence-Based Review of Levosalbutamol in the Treatment of Asthma (PubMed)

Frequently Asked Questions (FAQ)

Common questions about Levair (FAQ)

Q: How quickly does Levair start to work after taking it?

Levair is classified as an immediate-action medication designed for rapid relief. In clinical trials, improvement in lung function was observed to begin within about 30 minutes after administration of the dose.

Q: How long do the effects of a single dose of Levair last?

Levair is categorized as a Short-acting beta2-Adrenergic Receptor Agonist (SABA). According to the official regulatory information, the therapeutic effects of a single dose generally last for approximately 4 to 6 hours.

Q: Does Levair cause weight gain or changes in appetite?

Weight gain or changes in appetite are not listed among the most commonly reported side effects in the official product labeling. The most commonly documented adverse reactions relate to the nervous, cardiac, and respiratory systems, among others.

Q: Is it normal to feel slightly dizzy when first starting Levair?

Official safety information lists dizziness as one of the common adverse reactions reported in clinical trials. Regulatory warnings indicate that caution is advised for activities requiring mental alertness due to the potential for nervous system effects.

Q: Can Levair affect your sleep schedule?

Official safety documents include insomnia (difficulty sleeping) as a reported potential adverse reaction affecting the nervous system. This is a common effect observed with this class of medication.

Q: What common foods or supplements should be avoided while taking Levair?

The primary regulatory interaction documents state that there are no known interactions with food, specific metabolic enzymes, or supplements that are explicitly documented. Known interactions described in the primary regulatory documentation focus on specific prescription drug classes.

Q: Does alcohol consumption interfere with how Levair works?

The official regulatory documents state there are no known interactions with alcohol explicitly documented in the primary drug interaction sections. However, it is important to note that the product label does not explicitly list alcohol as a documented interaction.

Q: What happens if I forget to take a dose of Levair?

Official information regarding a missed dose of the inhalation solution typically provides guidance on when to resume the regular schedule, such as skipping a dose if the next one is soon. Specific instructions should always be reviewed on the prescription label or discussed with a healthcare professional.

Q: How does Levair work in the body at a cellular level?

Levair functions by acting as an agonist on beta2-adrenergic receptors found in the lungs. This binding activates a process involving a molecule called cyclic AMP, which ultimately leads to the relaxation of the smooth muscles in the airways, resulting in bronchodilation.

Q: What are the signs of an allergic reaction to Levair?

The official labeling highlights the risk of immediate hypersensitivity reactions. Signs of a serious allergic reaction may include hives, angioedema (swelling of the face, tongue, or throat), rash, or sudden difficulty breathing. These symptoms are considered serious and require prompt emergency medical attention.

Q: Does Levair affect blood pressure or heart rate?

Regulatory warnings note that Levair can potentially produce clinically significant cardiovascular effects, as with other beta-adrenergic agonists. These effects can include an increase in heart rate (tachycardia), palpitations, and changes in blood pressure in some patients.

Q: Can Levair be crushed or split if it's a tablet?

Levair is an inhalation medicine supplied either as a sterile nebulizer solution or a metered-dose inhaler (MDI). The official labeling and administration instructions are provided only for these inhalation forms, and do not include guidance for crushing or splitting a tablet form.

Q: What is the typical time frame for noticing the full benefit of Levair?

Levair is a short-acting rescue medication intended for rapid action. In studies of single doses, peak improvement in lung function was typically observed within 2 to 3 hours after administration.

Q: Is it possible for Levair to stop working over time?

Regulatory labeling indicates that an increased need for the medication may be a procedural indicator that necessitates reevaluation of the treatment plan. If the medication seems less effective, this should be noted as part of a treatment review.

Q: Are headaches a common side effect of Levair?

Yes, headache is explicitly listed in the official safety profile as one of the most common adverse reactions reported during clinical trials for the medication.

Q: Is Levair safe to use during pregnancy or while breastfeeding (general question)?

Official labeling states that there are no adequate and well-controlled studies of Levair in pregnant women. It is also unknown if the drug is excreted in human milk during lactation. The decision to use the medication during these periods involves carefully weighing the potential benefits against the risks.

Q: What precautions should people with kidney problems take when considering Levair?

Regulatory information advises caution in patients with impaired renal function, as the medication is substantially excreted by the kidney. Monitoring of kidney function may be deemed necessary by a healthcare provider.

Q: Is Levair available as a generic medicine?

Yes, Levalbuterol is the generic name for the active ingredient in Levair. It is available as an FDA-approved generic version, in addition to the branded product.

Q: What is the 'half-life' of Levair in the system?

The terminal half-life of (R)-albuterol, which is the active ingredient in Levair, is reported in pharmacokinetic studies to be approximately 3.3 to 4.0 hours.

Q: Does Levair show up on standard drug tests?

The active ingredient in Levair is a type of beta2-agonist, which is included on the World Anti-Doping Agency (WADA) Prohibited List. Use of the medication can therefore cause a positive test result for athletes in specific competitive settings.

Q: Why is my doctor asking me to have regular blood tests while on Levair?

Levair can potentially cause changes in blood chemistry, such as a temporary decrease in potassium levels (hypokalemia) and sometimes elevated blood glucose. Monitoring through blood tests may be necessary to watch for these metabolic effects, especially when Levair is combined with certain other medications like diuretics or steroids.

Q: Can taking Levair affect my ability to concentrate?

The official side effect profile includes central nervous system effects such as nervousness, tremor, and dizziness. Regulatory information notes that these symptoms may impair a person's ability to focus or concentrate.

Q: Is it safe to drive or operate machinery after taking Levair?

Regulatory information notes that if you experience central nervous system effects such as dizziness or tremor, activities like driving or operating machinery may be impaired. Caution is advised based on the documented side effects.

Q: What should I do if I accidentally take two doses of Levair close together?

Regulatory information warns that excessive use of beta-adrenergic agonists, including Levair, may lead to serious adverse effects. Symptoms of an overdose can include a worsening of common side effects like rapid heart rate (tachycardia) or tremor. Due to the risk of severe side effects, immediate emergency medical attention is necessary if an overdose is suspected.

How should Levair be stored and disposed of?

How to Store and Dispose of Levair?

Levair (levalbuterol) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The solution must not be frozen.

To ensure stability, the vials must be protected from light and stored in their original foil pouch until needed. Once the pouch is opened, any unused vials of the inhalation solution must be discarded after two weeks.

All Levair products must be kept out of the reach of children.

For disposal of unused or expired product, individuals should consult a healthcare professional or pharmacist. Aerosol canisters must not be punctured or incinerated.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levair found in:

A-Z Index: